Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

• Phyo T. Htoo,
• Helen Tesfaye,
• Sebastian Schneeweiss,
• Deborah J. Wexler,
• Brendan M. Everett,
• Robert J. Glynn,
• Niklas Schmedt,
• Lisette Koeneman,
• Anouk Déruaz-Luyet,
• Julie M. Paik,
• Elisabetta Patorno

Affiliations

Phyo T. Htoo

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Helen Tesfaye

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Sebastian Schneeweiss

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Deborah J. Wexler

Massachusetts General Hospital Diabetes Center, Harvard Medical School

Brendan M. Everett

Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School

Robert J. Glynn

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Niklas Schmedt

Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE

Lisette Koeneman

Global Medical Affairs, Lilly Deutschland GmbH

Anouk Déruaz-Luyet

Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE

Julie M. Paik

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Elisabetta Patorno

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School